Skip to content

STUDY COMPARING ONDANSETRON AND PALONOSETRON IN REDUCING VOMITING IN PATIENTS AFTER ENT SURGERIES

A PROSPECTIVE COMPARATIVE STUDY OF EFFICACY OF ONDENSETRON VERSUS PALANOSETRON FOR PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING IN PATIENTS POSTED FOR ELECTIVE OTORHINOLARYNGOLOGY SURGERIES UNDER GENERAL ANAESTHESIA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/063674
Enrollment
72
Registered
2024-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: palanosetron75 microgram 10min prior to induction of general anaesthesia: The number of episodes of nausea, retching and vomiting and side effects if any will be assessed postoperativel

Sponsors

DR SOMSUNDAR R G
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Aged between 18 to 60 years 2.ASA I and II category patients 3.Patients undergoing elective otorhinolaryngology surgeries under general anaesthesia 4.Patients willing to give informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1.Allergy to palonosetron and ondensetron 2.Use of antiemetics within 48 hours prior to surgery 3.Patient refusal 4.Patient with prolonged QT syndrome

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of ondansetron versus palonosetron in preventing postoperative nausea and vomiting in the first 24 hours using three scoring systems (nausea score, postoperative vomiting score, and postoperative nausea and vomiting score) in patients undergoing elective otorhinolaryngology surgeries under general anaesthesiaTimepoint: at base line , 2 hours , 6 hours , 12 hours , 24 hours

Secondary

MeasureTime frame
To measure the severity of nausea, need for rescue medication, patient’s satisfaction and incidence of adverse effects. Timepoint: 0 to 2 hrs, 2 to 6 hrs, 6 to 24 hrs

Countries

India

Contacts

Public ContactDR SHARMILA SHERIN

MANDYA INSTITUTE OF MEDICAL SCIENCES

somurg@gmail.com9686508877

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026